PENPULIMAB-KCQX
LaunchmAbpenpulimab
BLAINTRAVENOUSINJECTABLE
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
PENPULIMAB-KCQX (penpulimab) is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. First approved in 2025.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Penpulimab-kcqx is a humanized IgG1 monoclonal antibody that blocks PD-1 receptor signaling to restore anti-tumor immune responses. It binds to PD-1 and prevents interaction with PD-L1 and PD-L2 ligands, releasing inhibition of T-cell proliferation and cytokine production. This mechanism enables the immune system to recognize and attack tumor cells that would otherwise evade surveillance.
Launch
Early-stage launch presents opportunity for brand-building roles; competitive pressure at 30 suggests moderate but growing market intensity requiring focused commercial strategy.
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Started Apr 2025
72 enrolled
Advanced Pancreatic Cancer
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Started Jul 2024
54 enrolled
Soft Tissue SarcomaMelanoma
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
Started May 2024
3 enrolled
Advanced Malignant Neoplasm
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Started Jan 2024
75 enrolled
Colorectal Cancer
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
Started Sep 2023
59 enrolled
Nasopharyngeal Neoplasms
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.